{"text": ["AbbVie", "Rapidly", "Advancing", "Its", "2018", "Solid", "Tumor", "Portfolio"], "created_at": "2018-01-09 22:15:02"}
{"text": ["5", "Ways", "Gilead", "Sciences", "Plans", "to", "Return", "to", "Growth"], "created_at": "2018-01-09 22:07:31"}
{"text": ["Notable", "Tuesday", "Option", "Activity:", "MCK,", "ABBV,", "BIIB"], "created_at": "2018-01-09 22:06:25"}
{"text": ["AbbVie&apos;s", "Upadacitinib", "Gains", "Breakthrough", "Therapy", "Designation"], "created_at": "2018-01-09 21:37:09"}
{"text": ["Is", "AbbVie", "Stock", "Still", "A", "Strong", "Buy?"], "created_at": "2018-01-09 21:07:47"}
{"text": ["AbbVie\u2019s", "Venclexta", "for", "Chronic", "Lymphocytic", "Leukemia"], "created_at": "2018-01-09 20:45:09"}
{"text": ["AbbVie", "Expects", "Peak", "Sales", "of", "$7", "Billion", "for", "Imbruvica"], "created_at": "2018-01-09 19:10:52"}
{"text": ["4", "Best", "Marijuana", "Stocks", "to", "Play", "the", "Green", "Rush"], "created_at": "2018-01-09 19:03:42"}
{"text": ["Is", "AbbVie", "Stock", "Still", "A", "Strong", "Buy?"], "created_at": "2018-01-09 19:03:00"}
{"text": ["4", "Best", "Marijuana", "Stocks", "to", "Play", "the", "Green", "Rush"], "created_at": "2018-01-09 16:59:04"}
{"text": ["AbbVie\"s", "JAK1", "Inhibitor", "Granted", "FDA\"s", "Breakthrough", "Therapy"], "created_at": "2018-01-09 16:54:43"}
{"text": ["Ex-Dividend", "Reminder:", "Patterson", "Companies,", "AbbVie", "and", "Abbott", "Laboratories"], "created_at": "2018-01-09 16:04:47"}
{"text": ["Why", "AbbVie", "Is", "Focused", "on", "Expanding", "Risankizumab\u2019s", "Label", "for", "Multiple", "Immunology", "Indications"], "created_at": "2018-01-09 15:32:17"}
{"text": ["See", "what", "the", "IHS", "Markit", "Score", "report", "has", "to", "say", "about", "AbbVie", "Inc."], "created_at": "2018-01-09 13:06:00"}
{"text": ["Cramer's", "lightning", "round:", "Mercadolibre", "is", "even", "better", "tha..."], "created_at": "2018-01-09 00:00:00"}
